Buy-and-Bill vs Specialty Pharmacy for Infusion Practices

For infusion practices, buy-and-bill and specialty pharmacy carry two different risk profiles wearing similar clothes. One puts your practice's cash on the line before a payer confirms it'll pay you back. The other hands off that risk, and a good chunk of your revenue, to somebody else's supply chain. I've watched practices pick the wrong model for their payer mix and bleed working capital for a year before anyone traced it back to a front-end decision that got made without thinking it through.

Here's the baseline. In buy-and-bill, the practice purchases the drug from a distributor, administers it, then bills the payer for both the drug and the administration. You control what gets administered and you own the supply chain end to end. Medicare Part B pays most physician-administered drugs at ASP plus 6%, recalculated by CMS every quarter. Commercial payers don't follow that formula at all; whatever's in your contract is what you get, and every payer's contract looks different.

White bagging flips that. The payer's designated specialty pharmacy dispenses the drug and ships it to your infusion center. You administer it, but you never purchased it, so you never bill for the drug and you never see drug margin. Your revenue narrows down to the administration fee alone. There's a cousin arrangement called brown bagging, where the patient carries the drug from pharmacy to clinic themselves; once that drug passes through a patient's hands, nobody can verify how it was stored or whether the cold chain held. And there's a newer variant called clear bagging, where a pharmacy affiliated with the provider does the dispensing, which at least keeps chain of custody intact and lets the provider's pharmacy partner capture some dispensing revenue instead of losing it to the payer's PBM entirely.

None of these models are interchangeable, and none of them are yours to pick freely. Payer policy, state law, and your contract terms decide which one applies to a given patient and a given drug. That has to get confirmed before you order the drug, not after you've already administered it and are staring down a denial.

Where the drug margin actually comes from — and what can compress it

Drug margin is the spread between what you paid to acquire the drug and what the payer reimburses you for it. It's the entire financial case for buy-and-bill, so it's worth being precise about what actually drives it.

Say your acquisition cost on a drug is $10,000, and Medicare reimburses at ASP plus 6%, so you collect $10,600. That's a $600 margin on the encounter. Now take that same drug under 340B pricing, where your acquisition cost drops to $6,000. Same reimbursement, same $10,600. Your margin jumps to $4,600. Identical drug, identical claim, and the difference is purely about which acquisition program you have access to.

ASP reimbursement moves every quarter because CMS recalculates it. A downward adjustment compresses your margin on every buy-and-bill claim for that drug, immediately, across your whole patient panel. If you're running high volume on a handful of biologics with already-thin margins, you feel that quarterly reset in your bottom line before you've even seen the remittance advice. Commercial contracts add a second layer of instability on top of that: those rates are negotiated once and then sit there, sometimes for years, while ASP and acquisition costs keep moving underneath them. A contract that made sense at signing can quietly become a loser.

White bagging deletes your drug margin entirely rather than simply compressing it. For an ambulatory infusion center whose whole financial model assumes drug margin as a revenue line, that means a rebuild of the revenue model from the ground up. Which means the number you actually need isn't some blended average margin across your book. You need per-drug, per-payer margin, because that's the only number that tells you what a white-bagging mandate, or the next ASP cut, is really going to cost you.

The financial exposure buy-and-bill creates when claims go wrong

Here's the part that keeps practice administrators up at night. In buy-and-bill, you purchase the drug before you know for certain the claim will get paid. If that claim gets denied, you're holding the full acquisition cost with no path to get it back.

On high-cost biologics, per-encounter drug exposure runs anywhere from $5,000 to $50,000. That's not a line item you shrug off on a remittance report. One denied biologic claim can tie up more working capital than a full week of administration revenue, and that's before you factor in the time and staff hours spent appealing it.

The cash flow pressure is structural, not just a bad month. You buy the drug first. Reimbursement takes weeks, sometimes months. Any denial stretches that timeline further, and every day it stretches, that capital is sitting somewhere other than your bank account.

A few specific failure points create most of this exposure:

• Wrong J-code or wrong unit count, so reimbursement calculates against the wrong quantity or the wrong drug entirely

• Drug acquisition model mismatch, where the claim goes out as buy-and-bill but the payer actually required white bagging; these get miscategorized as coverage denials constantly, when really they were preventable at intake

• Missing or lapsed prior authorization, which deserves its own section and gets one below

• Underpayment, where the payer remits less than the contracted rate and nobody catches it without line-level reconciliation; left unchecked, it turns into a permanent write-off

Specialty pharmacy sidesteps all of this. You never own the drug, so there's no capital at risk when a claim gets denied. The trade is straightforward: lower ceiling, since there's no drug margin, for a lower floor, since there's no acquisition-cost exposure either. So the real question for any practice operator is whether your revenue cycle infrastructure actually protects the margin buy-and-bill promises you, or whether you're absorbing all the capital risk without consistently capturing the upside that's supposed to come with it.

What white bagging costs infusion centers beyond lost drug margin

Losing drug margin is the cost everybody sees coming. The costs that sneak up on practices are the ones baked into day-to-day operations once white bagging is in place.

Add-on payments that used to cover drug handling and storage overhead tend to disappear once a payer moves a drug to white bagging. According to NAIP survey data, the unreimbursed administrative waste tied to white bagging runs between $13,000 and $67,500 per practice. That's special handling, that's disposal of drugs that can't be used, and practices eat all of it with no mechanism to bill it back to anyone.

Operationally, things get more tangled, not less. If a patient doesn't pay their co-pay or coinsurance to the specialty pharmacy, the pharmacy simply doesn't ship the drug, and now your clinical staff is on the phone chasing down patient compliance before treatment can even happen. Dosing gets locked in at the moment the pharmacy dispenses it, so if a patient's weight has shifted and the dose needs adjusting, you can't do it chairside. You either delay treatment or you administer a dose that might be subtherapeutic. And chain of custody is impossible to verify once a drug has traveled through an external pharmacy's shipping process, especially under brown bagging, where the patient's the one carrying it.

The administrative load under white bagging is heavier than under buy-and-bill, not lighter. Your practice does less of the financially rewarding work and more of the logistical coordinating work. Clear bagging softens some of this, since dispensing stays inside a provider-affiliated pharmacy, but not every payer will accept it, and not every practice has the pharmacy infrastructure to run it. The bottom line: specialty pharmacy moves the complexity from billing over to logistics, and it takes revenue with it on the way out.

The payer policy environment that makes the model choice unstable

Practices don't get to choose their model in a vacuum. Payers increasingly dictate it through contract language, coverage policy, and PBM channel requirements, and that landscape keeps shifting under everyone's feet.

States have started pushing back. As of mid-2025, 12 states have banned mandatory white bagging and brown bagging policies outright, and roughly a dozen more have legislation working its way through debate right now. These bans aren't just about provider economics either; lawmakers are citing patient safety, specifically treatment delays, dosing inflexibility, and medication waste, as the driving concern.

Oncology gives us a useful reference point here. Buy-and-bill still dominates infused oncology almost completely, with 98.5% of infused oncology running under buy-and-bill. That tells you something real: in high-acuity clinical settings, resistance to white bagging holds up, both on clinical grounds and financial ones.

None of this sits still, though. Coverage policies get updated throughout the year. Authorization requirement lists change. Site-of-care restrictions keep getting more common. A practice that confirmed a drug's model status during contracting last year might be operating on information that's already stale. And on top of that, CMS expanded the Ambulatory Surgical Center fee schedule in 2025 to cover complex biologic infusions, opening up a 40 to 50% cost gap that favors freestanding centers over hospital outpatient departments. That's a reimbursement signal that could start reshaping how payers steer site-of-care decisions going forward.

The practical takeaway: figuring out which model a payer requires for a specific drug, and whether that requirement is even enforceable under your contract or legal in your state, is front-end work. It has to happen before the first authorization goes out the door. Practices that find out the applicable model at the billing stage, after the drug's already in the patient, have no recovery path left.

Why prior authorization is the hinge point for buy-and-bill viability

Prior authorization in buy-and-bill marks the moment your capital gets committed, because the drug gets purchased and administered before the payer has actually confirmed it'll cover it.

The burden itself is heavy. Providers typically spend close to two full business days a week just on authorization tasks, and a single PA request can take anywhere from a day to a full month to process. For infusion specifically, there are a few recurring ways this breaks down:

• Recurring treatment cycles need renewal authorizations, and if that renewal doesn't get submitted on time, later sessions go out without valid authorization on file, even though the underlying treatment regimen was already approved

• Payers update their PA requirement lists all year long, often without any notice, so a drug that didn't need authorization last month might need it this month

• Step therapy gets flagged even with a valid authorization in hand, if the clinical documentation doesn't clearly show the required prior therapy was tried and failed; the payer denies on medical necessity grounds regardless of the auth status

AI-driven payer review has sped up the denial timeline without making it any more accurate. Reviews that used to take three to five business days with a human reader now come back in hours. But per the AMA's 2025 Prior Authorization Survey, AI-generated denials happen at a rate 40% higher than human-reviewed decisions. There's a documented case of over 300,000 claims denied in under two months, which gives you a sense of what happens when AI review replaces human judgment at scale on the payer side. Separately, analysis of 2025 PA data found insurers denying a significant share of standard prior authorization requests across Medicare Advantage, Medicaid managed care, and the federally facilitated marketplace.

Authorization management for infusion has to start before the treatment cycle even begins. Trying to fix a lapsed authorization after the fact rarely works, and by then the drug cost is already spent regardless of outcome. Specialty pharmacy shifts some of this weight: under white bagging, the specialty pharmacy generally handles authorization for the drug itself, while your infusion center only manages authorization for the administration. That's a narrower scope of responsibility, though not a zero one.

How denial patterns differ between buy-and-bill and specialty pharmacy claims

Denials, broadly, have gotten worse across the board. Per Experian Health's 2025 State of Claims Report, overall claim denials rose from 30% in 2022 to 38% in 2024 and climbed past 11% again in 2025; initial denial rates hit 11.8% in 2024, up from 10.2% the year before. Medicare Advantage is where this shows up hardest, with MA denial rates spiking 4.8% from 2023 to 2024, compared to just 1.5% for commercial plans. If your payer mix leans heavily MA, that gap matters to you more than it does to the practice down the street.

Buy-and-bill has its own specific denial fingerprints. Drug acquisition model mismatches, where you billed buy-and-bill but the payer wanted white bagging, get labeled as coverage denials when they're really front-end intake errors that were entirely avoidable. J-code errors show up constantly, whether it's the wrong code, wrong units, or a code that doesn't match the diagnosis, and each variant needs its own fix. Authorization gaps on recurring treatment cycles surface weeks after the drug cost already hit your books. Medical necessity denials tied to step therapy are, at their root, incomplete clinical documentation problems rather than missing-auth problems. And eligibility lapses between the authorization date and the actual date of service show up often in recurring infusion schedules, where a lot can change over a few weeks.

Specialty pharmacy's denial profile is narrower, though not absent by any means. Denials there cluster around administration coding, site-of-care eligibility, and coordination breakdowns, like a drug shipping late or a patient's pharmacy co-pay sitting unresolved.

Here's the thing about denial patterns generally: they're payer-specific. A documentation gap that gets one commercial plan to deny a claim might not even register with another plan. If you're grouping all your denials into generic buckets, you're hiding the exact payer-level signal you need to stop the same denial from happening again next month. In most mid-market infusion organizations I've looked at, elevated denial rates trace back to a small, repeating set of root causes, not random noise. Buy-and-bill demands denial management that can isolate root cause down to the payer-drug-code level. Counting denials isn't enough.

What the AR ledger looks like differently under each model

Buy-and-bill AR looks completely different from specialty pharmacy AR, and if you're running both, your ledger needs to treat them that way.

Buy-and-bill AR carries high-dollar claims, longer aging cycles, and exposure that compounds fast if denials sit unworked. A single biologic claim worth $5,000 to $50,000 can throw off your entire AR aging report worse than dozens of routine administration-only claims combined. Reimbursement already takes weeks to months; add a denial and an appeal cycle on top, and your capital stays locked up in that drug cost the whole time. Underpayments are the quieter version of this problem: a payer remits less than the contract says, nobody catches it without line-level remittance reconciliation, and it gets posted, closed, and forgotten as a write-off that never gets appealed.

Specialty pharmacy AR runs lower dollar amounts per claim, since you're only billing for administration, and faster cycle times, but a much thinner total revenue pool. It's easier to manage. There's just less of it worth managing.

Which tells you something about where your attention has to go. If you're running buy-and-bill, a handful of high-dollar aging claims deserve daily attention, because letting one sit for an extra month costs you more than a stack of small specialty pharmacy claims ever could. Prioritize by dollar exposure and age together, not by claim count. A ledger full of small, clean specialty pharmacy claims can make your AR look healthy on the surface while a couple of stuck biologic claims are quietly doing real damage underneath. Platforms built specifically for this kind of work, such as Ruby RCM, a revenue cycle management tool purpose-built for infusion centers that handles claims, denials, and AR alongside prior authorization and benefits verification, are designed to surface that buried exposure before it ages into a permanent write-off.